The cell cycle checkpoint inhibitors in the treatment of leukemias

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

(2016) Giorgio Scagliotti et al.   INVESTIGATIONAL NEW DRUGS

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)

(2016) Y Jiang et al.   Blood Cancer Journal

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells

(2016) Jana Zemanova et al.   Oncotarget

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo

(2015) Wenxiu Qi et al.   CANCER BIOLOGY & THERAPY

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

(2015) Ilaria Iacobucci et al.   Journal of Hematology & Oncology

Ataxia-telangiectasia — A historical review and a proposal for a new designation: ATM syndrome

(2015) Hélio A.G. Teive et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells

(2015) Tri Nguyen et al.   LEUKEMIA RESEARCH

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated Leukemias

(2015) Nidal Muvarak et al.   MOLECULAR CANCER RESEARCH

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Non-coding recurrent mutations in chronic lymphocytic leukaemia

(2015) Xose S. Puente et al.   NATURE

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair

(2015) James B. Ford et al.   Oncotarget

Chemopreventive Effects of Korean Red Ginseng Extract on Rat Hepatocarcinogenesis

(2015) Hyemee Kim et al.   Journal of Cancer

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients

(2014) Nasir Kamat et al.   Cancer Cell International

ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

(2014) R. Josse et al.   CANCER RESEARCH

Radiosensitization of Human Leukemic HL-60 Cells by ATR Kinase Inhibitor (VE-821): Phosphoproteomic Analysis

(2014) Barbora Šalovská et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

(2014) Wenxiu Qi et al.   Journal of Hematology & Oncology

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

(2014) L Zhou et al.   LEUKEMIA

CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress

(2014) L M Sarmento et al.   ONCOGENE

Targeting ATR in DNA damage response and cancer therapeutics

(2013) Emmanouil Fokas et al.   CANCER TREATMENT REVIEWS

Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

(2013) C. G. Engelke et al.   CLINICAL CANCER RESEARCH

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia

(2013) Masatoshi Takagi et al.   DNA REPAIR

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

(2013) L. Chaudhuri et al.   HAEMATOLOGICA

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells

(2013) Svetlana Grabauskiene et al.   LUNG CANCER

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

(2013) M. A. Batey et al.   MOLECULAR CANCER THERAPEUTICS

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

(2013) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

(2013) A. A. Van Linden et al.   MOLECULAR CANCER THERAPEUTICS

The ATM protein kinase: regulating the cellular response to genotoxic stress and more

(2013) Yosef Shiloh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)

(2013) Jiřina Vávrová et al.   RADIATION AND ENVIRONMENTAL BIOPHYSICS

RNAi screening of the kinome with cytarabine in leukemias

(2012) R. Tibes et al.   BLOOD

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

(2012) A. Dolnik et al.   BLOOD

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

(2012) Cynthia X. Ma et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

(2012) I M Pires et al.   BRITISH JOURNAL OF CANCER

Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype

(2012) Christine Didier et al.   CANCER BIOLOGY & THERAPY

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

(2012) Remko Prevo et al.   CANCER BIOLOGY & THERAPY

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

(2012) Amy D Guertin et al.   Cancer Cell International

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma

(2012) M. R. Russell et al.   CANCER RESEARCH

Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells

(2012) Z. Korwek et al.   DNA REPAIR

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

(2012) H. J. Landau et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

(2012) S Origanti et al.   ONCOGENE

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

Activation of ATR and related PIKKs

(2011) Daniel A. Mordes et al.   CELL CYCLE

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter

(2011) D. Rossi et al.   HAEMATOLOGICA

Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase

(2011) Edward A. Nam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

(2011) Jean-Damien Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation

(2011) Shizhou Liu et al.   MOLECULAR CELL

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

The MRN complex in double-strand break repair and telomere maintenance

(2010) Brandon J. Lamarche et al.   FEBS LETTERS

Autophosphorylation and ATM Activation

(2010) Sergei V. Kozlov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genomic instability — an evolving hallmark of cancer

(2010) Simona Negrini et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

(2010) J Bartkova et al.   ONCOGENE

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy

(2009) C. Cavelier et al.   CANCER RESEARCH

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response

(2009) H. Nishida et al.   NUCLEIC ACIDS RESEARCH

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms

(2009) A Satyanarayana et al.   ONCOGENE

Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair

(2008) Annahita Sallmyr et al.   CANCER LETTERS

Mre11 Dimers Coordinate DNA End Bridging and Nuclease Processing in Double-Strand-Break Repair

(2008) R. Scott Williams et al.   CELL

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

(2008) Martin F. Lavin   NATURE REVIEWS MOLECULAR CELL BIOLOGY

ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

(2008) J Grosjean-Raillard et al.   ONCOGENE

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE